Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.71 |
| ▸ | PYGM | P11217 | 3/20 | 0.70 |
| ▸ | TK2 | O00142 | 3/20 | 0.65 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.51 |
| ▸ | TK1 | P04183 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CDA | P32320 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14853793 | 1.00 | DNPH1 (0.71) | DNPH1PYGMTK2SLC28A1SLC28A2 | |
| SCHEMBL263751 | 1.00 | DNPH1 (0.71) | DNPH1PYGMTK2SLC28A1SLC28A2 | |
| SCHEMBL14946378 | 1.00 | DNPH1 (0.71) | DNPH1PYGMTK2SLC28A1SLC28A2 | |
| SCHEMBL9465821 | 1.00 | DNPH1 (0.71) | DNPH1PYGMTK2SLC28A1SLC28A2 | |
| SCHEMBL14929135 | 1.00 | DNPH1 (0.71) | DNPH1PYGMTK2SLC28A1SLC28A2 | |
| SCHEMBL13519201 | 0.99 | PYGM (0.73) | DNPH1PYGMTK2SLC28A1SLC28A2 | |
| Uridine SCHEMBL29084594 | 0.91 | SLC28A1 (0.78) | DNPH1PYGMTK2SLC28A1SLC28A2 | |
| SCHEMBL1286250 | 0.91 | PYGM (0.69) | DNPH1PYGMTK2SLC28A1SLC28A2 | |
| SCHEMBL2577325 | 0.91 | PYGM (0.69) | DNPH1PYGMTK2SLC28A1SLC28A2 | |
| SCHEMBL1286252 | 0.91 | PYGM (0.69) | DNPH1PYGMTK2SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618064-B2 | Acetylated ribonucleic acids and uses thereof | HELIX NANOTECHNOLOGIES INC (US) | 2026-05-05 | — | — | US | claimed |
| US-20260108554-A1 | METHODS FOR REPROGRAMMING AND GENE EDITING CELLS | FACTOR BIOSCIENCE INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4720279-A2 | CIS-REGULATORY ELEMENTS OF TRANSLATION AND METHODS USING SAME | Yale University (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4716748-A2 | METHOD OF MODULATING MRNA TRANSLATION | Yale University (US) | 2026-04-01 | — | — | EP | claimed |
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | claimed |
| US-12551551-B2 | Compositions comprising α-factor prepro sequence and uses thereof | HELIX NANOTECHNOLOGIES INC (US) | 2026-02-17 | — | — | US | claimed |
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | ARCTURUS THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | claimed |
| EP-4665405-A1 | DNA COMPOSITIONS COMPRISING MODIFIED URACIL | Flagship Pioneering Innovations VII, LLC (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250346888-A1 | PROMOTER PROXIMAL SEQUENCES AND USES THEREOF FOR RNA MANUFACTURING | HELIX NANOTECHNOLOGIES INC (US) | 2025-11-13 | — | — | US | claimed |
| EP-4619531-A1 | SELF-REPLICATING RNA AND USES THEREOF | Trustees of Boston University (US) | 2025-09-24 | — | — | EP | claimed |
| US-8822146-B2 | Derivatization of biomolecules by covalent coupling of non-cofactor compounds using methyltransferases | VILNIUS UNIVERSITY (LT) | 2014-09-02 | — | — | US | claimed |
| EP-2414528-B1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | UNIV VILNIUS (LT) | 2014-05-07 | — | — | EP | claimed |
| US-20120094280-A1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2012-04-19 | — | — | US | claimed |
| EP-0653439-B1 | Stabilized oligonucleotids and the use thereof | AVENTIS PHARMA GMBH (DE) | 2004-04-28 | — | — | EP | claimed |
| EP-0661291-B1 | Solid phase synthesis of oligoribonucleotide | AVENTIS PHARMA GMBH (DE) | 2001-03-07 | — | — | EP | claimed |
| US-5652358-A | Solid-phase synthesis of oligoribonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | claimed |
| EP-0770144-A1 | NUCLEIC ACID AMPLIFICATION METHOD USING A MODIFIED NUCLEOSIDE, AND DETECTION OF THE AMPLIFICATION PRODUCT USING ANTIBODIES | PARTEUROP DEVELOPPEMENT (FR) | 1997-05-02 | — | — | EP | claimed |
| WO-1996003526-A1 | NUCLEIC ACID AMPLIFICATION METHOD USING A MODIFIED NUCLEOSIDE, AND DETECTION OF THE AMPLIFICATION PRODUCT USING ANTIBODIES | PARTEUROP DEVELOPPEMENT (FR) | 1996-02-08 | — | — | WO | claimed |
| EP-0661291-A1 | Solid phase synthesis of oligoribonucleotide | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-07-05 | — | — | EP | claimed |
| EP-0653439-A2 | Stabilized oligonucleotids and the use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108554-A1 | METHODS FOR REPROGRAMMING AND GENE EDITING CELLS | B2M, MYADM, CD74 | DNPH1 3129/4885PYGM 1074/4885TK2 1615/4885 |
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | IGF2BP3, SERPINC1, IGF2BP2 | DNPH1 3822/4885PYGM 3892/4885TK2 1650/4885 |
| US-20120094280-A1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | EZH1, DOHH, BHMT2 | DNPH1 123/4885PYGM 1880/4885TK2 330/4885 |
| US-12551551-B2 | Compositions comprising α-factor prepro sequence and uses thereof | UPF1, CPSF1, HM13 | DNPH1 2954/4885PYGM 1524/4885TK2 1633/4885 |
| US-12618064-B2 | Acetylated ribonucleic acids and uses thereof | RNMT, TRDMT1, TRMT1L | DNPH1 2976/4885PYGM 1926/4885TK2 425/4885 |
| US-20250346888-A1 | PROMOTER PROXIMAL SEQUENCES AND USES THEREOF FOR RNA MANUFACTURING | RNGTT, NSUN2, CPSF6 | DNPH1 2996/4885PYGM 1876/4885TK2 1333/4885 |
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | OTC, OAT, POLRMT | DNPH1 1163/4885PYGM 1852/4885TK2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.